{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:12:27Z","timestamp":1793967147767,"version":"4.8.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"35","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000056","name":"National Institute of Nursing Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000056","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1U01NR020555"],"award-info":[{"award-number":["1U01NR020555"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Chimeric antigen receptor T-cell (CAR-T) therapies are cellular immunotherapies that improve survival in patients with relapsed haematologic malignancies. However, their association with major adverse cardiovascular events (MACE) has received limited study, particularly in older adults. This study investigated the incidence of MACE, associated risk factors, and their impact on survival among older patients undergoing CAR-T in the USA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medicare fee-for-service beneficiaries over 65 who received inpatient CAR-T therapy between 2018 and 2023 were included. Baseline characteristics were assessed during the 12 months preceding CAR-T. MACE were defined as a composite of acute heart failure (HF), cardiogenic shock, myocardial infarction, cardiac tamponade, ventricular arrhythmia, complete heart block, or stroke. Multivariable models were adjusted for demographics, malignancy type, and baseline cardiovascular comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 3292 patients receiving CAR-T, 191 (5.8%) had MACE. Most common events were acute HF (3.1%), followed by ischaemic (1.3%) and haemorrhagic stroke (1%). Pre-treatment atrial fibrillation\/flutter [adjusted odds ratio (aOR) 1.52 (1.08\u20132.16)], cardiomyopathy [aOR 2.49 (1.75\u20133.54)], and cerebrovascular disease [aOR 2.40 (1.30\u20134.43)] were independently associated with MACE. In 2021\u201323, MACE were also associated with immune effector cell-associated neurotoxicity syndrome and higher-grade cytokine release syndrome. MACE were associated with higher in-hospital mortality [aOR 16.9 (11.0\u201326.1)] and 1-year mortality after discharge [adjusted hazard ratio 1.91 (1.46\u20132.49)].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the largest national sample of older adults receiving CAR-T, MACE occurred in 5.8% of patients and were associated with increased in-hospital and 1-year mortality. Further investigation into preventive and mitigating measures is needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehag394","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:39:37Z","timestamp":1778067577000},"page":"4957-4969","source":"Crossref","is-referenced-by-count":5,"title":["Chimeric antigen receptor T-cell therapy and cardiovascular outcomes in US Medicare beneficiaries"],"prefix":"10.1093","volume":"47","author":[{"given":"Raja","family":"Zaghlol","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Disease, Washington University School of Medicine , 660 South Euclid Avenue, Campus Box 8086, St.Louis, MO 63110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6083-3579","authenticated-orcid":false,"given":"Elena","family":"Deych","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Disease, Washington University School of Medicine , 660 South Euclid Avenue, Campus Box 8086, St.Louis, MO 63110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A","family":"Ladin","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Disease, Washington University School of Medicine , 660 South Euclid Avenue, Campus Box 8086, St.Louis, MO 63110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1009-2247","authenticated-orcid":false,"given":"David A","family":"Russler-Germain","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine , St.Louis, MO ,","place":["USA"]},{"name":"Alvin J. Siteman Cancer Center, Washington University School of Medicine , 4500 Forest Park Avenue, St.Louis, MO, 63108 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Schiffer","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Disease, Washington University School of Medicine , 660 South Euclid Avenue, Campus Box 8086, St.Louis, MO 63110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nischit","family":"Baral","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Columbia University, Mount Sinai Medical Center , Miami, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6678-7764","authenticated-orcid":false,"given":"R J","family":"Waken","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Washington University School of Medicine , St.Louis, MO ,","place":["USA"]},{"name":"Center for Advancing Health Services, Policy & Economics Research, Washington University School of Medicine , St.Louis, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6628-9981","authenticated-orcid":false,"given":"Bonnie","family":"Ky","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3779-8653","authenticated-orcid":false,"given":"Karen E","family":"Joynt Maddox","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Disease, Washington University School of Medicine , 660 South Euclid Avenue, Campus Box 8086, St.Louis, MO 63110 ,","place":["USA"]},{"name":"Center for Advancing Health Services, Policy & Economics Research, Washington University School of Medicine , St.Louis, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7371-5742","authenticated-orcid":false,"given":"Joshua D","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Disease, Washington University School of Medicine , 660 South Euclid Avenue, Campus Box 8086, St.Louis, MO 63110 ,","place":["USA"]},{"name":"Alvin J. Siteman Cancer Center, Washington University School of Medicine , 4500 Forest Park Avenue, St.Louis, MO, 63108 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"2026091519574612300_ehag394-B1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"2026091519574612300_ehag394-B2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2026091519574612300_ehag394-B3","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.4161\/onci.22524","article-title":"How do CARs work?: early insights from recent clinical studies targeting CD19","volume":"1","author":"Davila","year":"2012","journal-title":"Oncoimmunology"},{"key":"2026091519574612300_ehag394-B4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2026091519574612300_ehag394-B5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s1470-2045(21)00591-x","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026091519574612300_ehag394-B6","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/s0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"2026091519574612300_ehag394-B7","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"2026091519574612300_ehag394-B8","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/eurheartj\/ehac106","article-title":"Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies","volume":"43","author":"Totzeck","year":"2022","journal-title":"Eur Heart J"},{"key":"2026091519574612300_ehag394-B9","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014","article-title":"Cardiotoxicity of T-cell antineoplastic therapies: JACC: CardioOncology primer","volume":"4","author":"Ganatra","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026091519574612300_ehag394-B10","doi-asserted-by":"publisher","first-page":"e2437222","DOI":"10.1001\/jamanetworkopen.2024.37222","article-title":"Cardiovascular events after chimeric antigen receptor T-cell therapy for advanced hematologic malignant neoplasms: a meta-analysis","volume":"7","author":"Koeckerling","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026091519574612300_ehag394-B11","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026091519574612300_ehag394-B12","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1161\/circulationaha.120.048100","article-title":"Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin Lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"key":"2026091519574612300_ehag394-B13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular effects of CAR T cell therapy: a retrospective study","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncol"},{"key":"2026091519574612300_ehag394-B14","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaccao.2023.07.009","article-title":"Incidence of MACE in patients treated with CAR-T cell therapy: a prospective study","volume":"5","author":"Lefebvre","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2026091519574612300_ehag394-B15","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1182\/bloodadvances.2023009766","article-title":"Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma","volume":"7","author":"Lee","year":"2023","journal-title":"Blood Adv"},{"key":"2026091519574612300_ehag394-B16","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy","volume":"78","author":"Goldman","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026091519574612300_ehag394-B17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/ejh.70040","article-title":"Predictive factors and baseline risk stratification for CAR-T cell therapy-related cardiovascular toxicity","volume":"116","author":"Farmakis","year":"2026","journal-title":"Eur J Haematol"},{"key":"2026091519574612300_ehag394-B18","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026091519574612300_ehag394-B19","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3324\/haematol.2021.280009","article-title":"Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma","volume":"107","author":"Steiner","year":"2022","journal-title":"Haematologica"},{"key":"2026091519574612300_ehag394-B20","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/eurheartj\/ehad117","article-title":"Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients","volume":"44","author":"Mahmood","year":"2023","journal-title":"Eur Heart J"},{"key":"2026091519574612300_ehag394-B21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40959-023-00170-5","article-title":"Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-cell therapy: an exploratory study","volume":"9","author":"Lee","year":"2023","journal-title":"Cardiooncology"},{"key":"2026091519574612300_ehag394-B22","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.1182\/bloodadvances.2024013849","article-title":"Cardiovascular toxicities associated with novel cellular immune therapies","volume":"8","author":"Munir","year":"2024","journal-title":"Blood Adv"},{"key":"2026091519574612300_ehag394-B23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002303","article-title":"Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma","volume":"9","author":"Brammer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026091519574612300_ehag394-B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102504","article-title":"Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study","volume":"69","author":"Korell","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026091519574612300_ehag394-B25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/ejh.14088","article-title":"Myocardial strain is associated with adverse cardiac events in patients treated with chimeric antigen receptor (CAR) T-cell therapy","volume":"112","author":"Patel","year":"2024","journal-title":"Eur J Haematol"},{"key":"2026091519574612300_ehag394-B26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2991\/chi.k.210718.001","article-title":"High sensitivity troponin T and NT-proBNP in patients receiving chimeric antigen receptor (CAR) T-cell therapy","volume":"3","author":"Hu","year":"2021","journal-title":"Clin Hematol Int"},{"key":"2026091519574612300_ehag394-B27","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"2026091519574612300_ehag394-B28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41577-022-00714-3","article-title":"Inflammatory cytokines and cardiac arrhythmias: the lesson from COVID-19","volume":"22","author":"Lazzerini","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"2026091519574612300_ehag394-B29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.36401\/jipo-20-10","article-title":"Cardiovascular complications of chimeric antigen receptor T-cell therapy: the cytokine release syndrome and associated arrhythmias","volume":"3","author":"Simbaqueba","year":"2020","journal-title":"J Immunother Precis Oncol"},{"key":"2026091519574612300_ehag394-B30","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.bbmt.2020.08.036","article-title":"Cardiovascular events associated with chimeric antigen receptor T cell therapy: cross-sectional FDA adverse events reporting system analysis","volume":"26","author":"Guha","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026091519574612300_ehag394-B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101830","article-title":"Risk profiles and incidence of cardiovascular events across different cancer types","volume":"8","author":"Mitchell","year":"2023","journal-title":"ESMO Open"},{"key":"2026091519574612300_ehag394-B32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T cell therapy\u2013related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity?","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncol"},{"key":"2026091519574612300_ehag394-B33","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41409-022-01562-4","article-title":"Profile of capillary-leak syndrome in patients received chimeric antigen receptor T cell therapy","volume":"57","author":"Feng","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"2026091519574612300_ehag394-B34","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1182\/blood-2018-99-117602","article-title":"Profile of capillary-leak syndrome in patients received chimeric antigen receptor T cell Therapy","volume":"132","author":"Hu","year":"2018","journal-title":"Blood"},{"key":"2026091519574612300_ehag394-B35","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.bbmt.2018.05.014","article-title":"Cardiac profile of chimeric antigen receptor T cell therapy in children: a single-institution experience","volume":"24","author":"Burstein","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026091519574612300_ehag394-B36","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"2026091519574612300_ehag394-B37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"2026091519574612300_ehag394-B38","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"2026091519574612300_ehag394-B39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1182\/blood-2018-02-769000","article-title":"Inflammation, von Willebrand factor, and ADAMTS13","volume":"132","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"2026091519574612300_ehag394-B40","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.jtha.2024.03.021","article-title":"A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy","volume":"22","author":"Bindal","year":"2024","journal-title":"J Thromb Haemost"},{"key":"2026091519574612300_ehag394-B41","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"2026091519574612300_ehag394-B42","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","article-title":"Mechanisms of cardiovascular toxicities associated with immunotherapies","volume":"128","author":"Baik","year":"2021","journal-title":"Circ Res"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/35\/4957\/68397080\/ehag394.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/35\/4957\/68397080\/ehag394.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:57:53Z","timestamp":1789516673000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/35\/4957\/8694626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":42,"journal-issue":{"issue":"35","published-online":{"date-parts":[[2026,5,26]]},"published-print":{"date-parts":[[2026,9,16]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag394","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,14]]},"published":{"date-parts":[[2026,5,26]]}}}